RS Oncology Announces Positive Data from a Phase 1 Clinical Trial of RSO-021, a First-in-Class Therapeutic for Malignant Pleural Mesothelioma

Contributed by: Business Wire

Logo

Images

Professor Dean Fennell, principal investigator, presents results from the Phase 1 MITOPE clinical study of a first-in-human, and potential first-in-class therapeutic, RSO-021. (Photo: Business Wire)

Business Wire embedded0

Tags

Oncology

Health

Infectious Diseases

Hospitals

Radiology

Pharmaceutical

Biotechnology

RS Oncology

More Like This

Prof. Dean Fennell, Director of the Mesothelioma Research Programme at Leicester University Hospitals in the lab with Dr. Joanna Dzialo and Dr. Aleksandra Bzura. The research and clinical teams are investigating RSO-021 anticancer activity in patients with malignant pleural mesothelioma and metastatic disease to the lung. (Photo: Dan Ryan)

RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung

AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart)

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients

Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting